


## Supporting Information

### Title

### Dual targeting of folate receptor-expressing glioma tumor-associated macrophages and epithelial cells in brain using carbon nanosphere-cationic folate nanoconjugate

Chandra Kumar Elechalawar, Dwaipayan Bhattacharya, Mohammed Tanveer Ahmed, Halley Gora Ravuri, Kathyayani Sreedharan, Piyush Chaturbedy, Sarmistha Halder Sinha, Madhan Mohan Chandra Sekhar Jaggarapu, Sumana Chakrabarty, Muthusamy Eswaramoorthy, Tapas K. Kundu, Rajkumar Banerjee

### Synthetic Scheme of C8:



**Scheme 1:** Synthesis of C8: Reagents and conditions; (A) 1-Bromo octane, K<sub>2</sub>CO<sub>3</sub> in Ethyl Acetate, 60 °C, 48 h. (B) CH<sub>3</sub>I in Dry CHCl<sub>3</sub>, 12 h; (C) Dry DCM, TFA (2:1; v/v), 0 °C, 3h. (D) Amberlyst A-26 for Cl<sup>-</sup> ion exchange (E) CH<sub>3</sub>COCl, Triethyl amine, Dry CH<sub>2</sub>Cl<sub>2</sub>.

### Synthesis of C8 (*N*-(2-acetamidoethyl)-*N*-methyl-*N*-octyloctan-1-aminium chloride

(Scheme 1):

**Step-1: Synthesis of tert-butyl (2-(di(octyl)amino) ethyl) carbonate (Compound-2):**

Monoboc-protected ethylenediamine (Compound-1, 1.8g) was added to Ethyl Acetate (20ml).

To this mixture K<sub>2</sub>CO<sub>3</sub> (6.4 g , 4eq) followed by 1-Bromo octane was added and stirred at

65 °C for 48 h. Reaction mass was filtered and the ethyl acetate was evaporated to get crude. Purification is done by column chromatographic separation using 60-120 mesh silica gel and 1% Methanol-Chloroform (v/v) as eluent. The separation yielded compound-2 as colourless liquid (3g, 70% yield).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : δ/ppm = 0.9 [m, 6H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-]; 1.1–1.6 [bs, 20H, -(CH<sub>2</sub>)<sub>10</sub>-; m, 9H, CO-O-C(CH<sub>3</sub>)<sub>3</sub>]; 1.5 [m, 4H, -CH<sub>2</sub>-N-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>4</sub> ]; 2.3–2.5 [m, 4, -CH<sub>2</sub>-N-(CH<sub>2</sub>)<sub>2</sub>-(CH<sub>2</sub>)<sub>2</sub>-]; 2.5 [t, 2H, -NH-CH<sub>2</sub>-CH<sub>2</sub>-N-(CH<sub>2</sub>)<sub>2</sub>- ]; 3.2 [m, 1H, -NH-CH<sub>2</sub>-CH<sub>2</sub>-N-(CH<sub>2</sub>)<sub>2</sub>- ]; 3.6 [t, 2H, -NH-CH<sub>2</sub>-CH<sub>2</sub>-N-(CH<sub>2</sub>)<sub>2</sub>-];

ESI-MS: m/z = 386 [M+H]<sup>+</sup> for C<sub>23</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>

**Step-2 :Synthesis of N-(2-((tert-butoxycarbonyl)amino)ethyl)-N-methyl-N-octyloctan-1-aminium iodide (3):** Compound-2, (1.8g) was added to methyl iodide (5ml) and stirred at room temperature for 12h. Methyl iodide was evaporated to get crude. Purification is done by column chromatographic separation using 60-120 mesh silica gel and 2% Methanol-Chloroform (v/v) as eluant. The separation yielded compound-3 as white solid (2.5g, 80% yield).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ/ppm = 0.9 [m, 6H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-]; 1.1-1.6 [bs, 20H, -(CH<sub>2</sub>)<sub>10</sub>-; m, 9H, CO-O-C(CH<sub>3</sub>)<sub>3</sub>]; 1.5 [m, 4H, -CH<sub>2</sub>-N-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>4</sub> ]; 3.2-3.3 [s, 3, -CH<sub>2</sub>-N(CH<sub>3</sub>)-(CH<sub>2</sub>)<sub>2</sub>-(CH<sub>2</sub>)<sub>2</sub>-]; 3.4-3.6 [m, 4H, -CH<sub>2</sub>-N(CH<sub>3</sub>)-(CH<sub>2</sub>)<sub>2</sub>-(CH<sub>2</sub>)<sub>2</sub>-]; 3.6-3.8 [m, 4H, -NH-CH<sub>2</sub>-CH<sub>2</sub>-N-(CH<sub>2</sub>)<sub>2</sub>-];

ESI MS: m/z = 400 [M – I]<sup>+</sup> for C<sub>24</sub>H<sub>51</sub>N<sub>2</sub>O<sub>2</sub>

**Step-3: Synthesis of N1-methyl-N1,N1-dioctylethane-1,2-diaminium chloride (4)**

Compound-3, (2g) was dissolved in 2 mL dry CHCl<sub>3</sub>, and to that 1 mL trifluoroacetic acid (TFA) was added and the mixture was allowed to stir for 3 h at 0°C. TFA was removed with nitrogen flow and the residue was subjected to chloride ion exchange chromatography over amberlyst A-26 chloride ion exchange resin. The compound 4 was obtained after chloride ion exchange (1.2 g, 80% yield) directly continued to next step.

**ESI-MS:**  $m/z = 300 [M - 2Cl]^+$  for  $C_{19}H_{43}N_2$ .

**Step-4: Synthesis of C8:**

Compound-4 was dissolved in Dry  $CH_2Cl_2$  and to this mixture Acetyl Chloride was added. followed by the addition of Triethylamine (0.459g, 2eq) and The reaction was stirred for 2h at  $0^\circ C$ . Then 1N, HCl 20 mL was added and the crude was extracted by  $CHCl_3$  dried and purified by using 60-120 mesh silica gel and 2% Methanol-Chloroform (v/v) as eluant.

**$^1H$  NMR (300 MHz,  $CDCl_3$ ):**  $\delta/ppm = 0.9$  [m, 6H,  $CH_3-(CH_2)_7-$ ]; 1.1-1.6 [bs, 20H,  $-(CH_2)_{10}$ ]; 1.5 [m, 4H,  $-CH_2-N-CH_2-(CH_2)_4$ ]; 2.0 [s, 3H,  $CH_3CO$ ]; 3.1-3.2 [s, 3H,  $-CH_2-N(CH_3)-(CH_2)_2-(CH_2)_2-$ ]; 3.2-3.4 [m, 6H,  $-CH_2-CH_2-N(CH_3)-(CH_2)_2-(CH_2)_2-$ ]; 3.6-3.7 [m, 2H,  $-NH-CH_2-CH_2-N(CH_3)-(CH_2)_2-$ ];

**ESI-MS:**  $m/z = 341.35 [M+H]^+$  for  $C_{21}H_{45}N_2O$

**Characterization of CSP-F8-DOX (CFD) through FTIR analysis:**

Functional group analysis of DOX containing targeted carbon nanospheres (CFD) was performed by FTIR spectrum. Peaks obtained at 3258, 1695, 1645, 1606, 1510 and 1122  $cm^{-1}$  are corresponding to O-H, C=O, amine groups of pteridine ring and either C=N or C=C of F8 (Figure S1) whereas in case of CSP we found peaks at 1005, 807, 588 belong to C-O-C and polymerized OH groups in CSPs, respectively. Importantly, we found additional peak at 1119.3  $cm^{-1}$  for the F8 in CSP-F8. 1670  $cm^{-1}$  in DOX loaded CSP (i.e., CD) could be due to hydrophilic interactions between C=O and other hydrophilic groups such as OH and  $NH_2$ . Further, F8 and DOX loaded CSPs exhibited similar peaks.




Figure S1. FTIR- Spectrum of different CSPs along with F8




Figure S2. Stability of CFD in different serum concentrations along with PBS




Figure S3. Standard curve for F8




Figure S4. Standard curve for DOX







Figure S5. A) Dose dependent absorption spectra of DOX. Absorption starts at 300-700 nm with abs max at 495 nm. Corresponding standard curve for the confirmation of drug loading as a inset. B) UV-VIS spectra of different CSP conjugates.



**Figure S6:** Fate of free DiR dye intraperitoneally injected in mice: No gross change of the fate of free DiR dye after 6h of IP injection. In a tumor bearing mice, after 24h of IP injection free DiR dye invaded adjoining tissues such as liver, tumor mass etc. But, free DiR dye could not gain access to brain even after 24h post-injection.



**Figure S7.** F4/80 staining in tumor region of orthotopic GL261 glioma bearing mice. This indicates the presence of TAM in glioma lesions in brain.



**Figure S8.** Chemokine expressions in brain tumor lysates developed from orthotopic GL261 glioma tumor bearing mice treated with different groups.




Figure S9: <sup>1</sup>H - NMR (300 MHz, CDCl<sub>3</sub>) Spectra of C8




Figure S10: ESI-Mass Spectra of C8



## References:

- S1. Yuan-Jia Pan, Dian Li, Sha Jin, Chuan Wei, Ke-Yi Wu, Jia Guo and Chang-Chun Wang. Folate-conjugated poly(N-(2-hydroxypropyl)-methacrylamide-co-methacrylic acid) nanohydrogels with pH/redox dual-stimuli response for controlled drug release. *Polym. Chem.*, 2013, 4, 3545–3553
- S2. G. Ali Mansoori 1, Kenneth S. Brandenburg 1 and Ali Shakeri-Zadeh. A Comparative Study of Two Folate-Conjugated Gold Nanoparticles for Cancer Nanotechnology Applications. *Cancers* **2010**, 2, 1911-1928.
- S3. S. Sanyakamdhorn, D. Agudelo & H.A. Tajmir-Riahi. Review on the targeted conjugation of anticancer drugs doxorubicin and tamoxifen with synthetic polymers for drug delivery. *J. Biomol. Struct. Dyn*, **2016**, 145, 55-63.